FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, namely to magnetic resonance diagnostics, and can be used for diagnosing oncological diseases in a subject. That is ensured by introducing a diagnostic preparation containing a deuterated derivative of a natural amino acid with a branched side chain and/or a pharmaceutically acceptable salt thereof. Deuterated derivative - a compound containing deuterium bonded to a carbon atom in at least one position in an amount greater than its natural content. Also disclosed is a diagnostic technique for oncological diseases using a diagnostic preparation.
EFFECT: group of invention enables performing the diagnosis of oncological diseases by magnetic resonance imaging and/or magnetic resonance spectroscopy on deuterium nuclei.
26 cl, 1 tbl, 6 ex, 4 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PREPARATION FOR MAGNETIC RESONANCE IMAGING CONTAINING DEUTERATED SARCOSINE, AND DIAGNOSTIC TECHNIQUE USING SAID PREPARATION | 2018 |
|
RU2738873C2 |
| PREPARATION FOR MAGNETIC-RESONANCE DIAGNOSTICS OF F CANCEROUS DISEASES COMPRISING DEUTERATED 2-AMINO-2-METHYLPROPIONIC ACID AND/OR 2-(N-METHYLAMINO)-2-METHYLPROPIONIC ACID AND A DIAGNOSTIC METHOD USING THE PREPARATION | 2017 |
|
RU2663286C1 |
| PREPARATION FOR MAGNETIC RESONANCE DIAGNOSTICS OF ONCOLOGICAL DISEASES CONTAINING DEUTERATED 3-O-METHYLGLUCOSE, AND DIAGNOSTIC METHOD USING SAID PREPARATION | 2017 |
|
RU2718052C2 |
| DEUTERATED HETEROCYCLIC COMPOUNDS AND USE THEREOF AS IMAGING MEANS | 2015 |
|
RU2696492C2 |
| DEUTERATED HETEROCYCLIC COMPOUNDS AND THEIR USE AS IMAGING TOOLS | 2015 |
|
RU2791900C1 |
| COMPOUND FOR DIAGNOSING TUMOURS EXPRESSING PSMA AND COMPOSITION BASED THEREON | 2019 |
|
RU2730507C1 |
| DYETHERNED PHENYLAMINOPYRIMIDINE AND PHARMACEUTICAL COMPOSITION CONTAINING SUCH CONNECTION | 2014 |
|
RU2633694C2 |
| DEUTERATED ANALOGUES OF ACETYLEUCINE | 2019 |
|
RU2810793C2 |
| NEW DERIVATIVES OF OXYNTOMODULIN AND PHARMACEUTICAL COMPOSITION FOR TREATING OBESITY | 2012 |
|
RU2612906C2 |
| MODULATING AGENT FOR AGGREGATION OF β-AMYLOID FOR AGGREGATION INHIBITION OF NATURAL β-AMYLOID OR FOR TREATMENT OF SUBJECT WITH DISORDER ASSOCIATED WITH β-AMYLOIDOSIS, PHARMACEUTICAL COMPOSITION AND METHOD FOR DETECTION OF NATURAL β-AMYLOID PEPTIDE IN BIOLOGICAL SAMPLE | 2000 |
|
RU2260599C2 |
